Drug Profile

BPP 1001

Alternative Names: BPP-1001

Latest Information Update: 09 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bioscience Pharma Partners
Class Anti-inflammatories; Small molecules
Mechanism of Action 5-lipoxygenase-activating protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Neurological disorders

Most Recent Events

09 Jun 2026 BPP 1001 is still in preclinical trials for Neurological-disorders in USA (Bioscience Pharma pipeline, June 2026)
09 Jun 2026 Pharmacodynamics data from preclinical studies in Neurological disorders released by Bioscience Pharma (Bioscience Pharma pipeline, June 2026)
28 Jan 2025 No recent reports of development identified for preclinical development in Neurological-disorders in USA (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com